Seth B. Coffelt

Dr. Seth B. Coffelt

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2016 in Nature Reviews Cancer
Verified
Journal Article
Closed access
SCSeth B. Coffelt
Seth B. Coffelt
MWMax D. Wellenstein
Max D. Wellenstein
KVKarin E. de Visser
Karin E. de Visser

30 March 2015 in Nature
Verified
Journal Article
Open access
PDF file
SCSeth B. Coffelt
Seth B. Coffelt
KKKelly Kersten
Kelly Kersten
CDChris W. Doornebal
Chris W. Doornebal
JWJorieke Weiden
Jorieke Weiden
KVKim Vrijland
Kim Vrijland
KVKarin E de Visser
Karin E de Visser
Tumours maximize their chance of metastasizing by evoking a systemic inflammatory cascade in mouse models of spontaneous breast cancer metastasis. That tumorigenesis can be closely linked to an inflammatory microenvironment has been well established. In a new study, Karin de Visser and colleagues estimate the more systemic inflammatory effects observed in a mouse model of breast cancer. They find that interleukin (IL)-1β expression in tumours elicits IL-17 expression in γδ T cells at a local level, which through granulocyte colony-stimulating factor production promotes systemic accumulation of neutrophils in multiple organs. Interfering with this cascade of events, for example at the level of neutrophil activation, reduces lung and lymph node metastases in this breast cancer model. These findings illustrate the perhaps wider than anticipated systemic effects elicited by localized tumours, at the same time offering multiple points of potential therapeutic interference. Metastatic disease remains the primary cause of death for patients with breast cancer. The different steps of the metastatic cascade rely on reciprocal interactions between cancer cells and their microenvironment. Within this local microenvironment and in distant organs, immune cells and their mediators are known to facilitate metastasis formation1,2. However, the precise contribution of tumour-induced systemic inflammation to metastasis and the mechanisms regulating systemic inflammation are poorly understood. Here we show that tumours maximize their chance of metastasizing by evoking a systemic inflammatory cascade in mouse models of spontaneous breast cancer metastasis. We mechanistically demonstrate that interleukin (IL)-1β elicits IL-17 expression from gamma delta (γδ) T cells, resulting in systemic, granulocyte colony-stimulating factor (G-CSF)-dependent expansion and polarization of neutrophils in mice bearing mammary tumours. Tumour-induced neutrophils acquire the ability to suppress cytotoxic T lymphocytes carrying the CD8 antigen, which limit the establishment of metastases. Neutralization of IL-17 or G-CSF and absence of γδ T cells prevents neutrophil accumulation and downregulates the T-cell-suppressive phenotype of neutrophils. Moreover, the absence of γδ T cells or neutrophils profoundly reduces pulmonary and lymph node metastases without influencing primary tumour progression. Our data indicate that targeting this novel cancer-cell-initiated domino effect within the immune system—the γδ T cell/IL-17/neutrophil axis—represents a new strategy to inhibit metastatic disease.

17 July 2008 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
CMCriag Murdoch
Criag Murdoch
Munitta MuthanaMunitta Muthana
Munitta Muthana
SCSeth B. Coffelt
Seth B. Coffelt
CLClaire E. Lewis
Claire E. Lewis
Bone marrow-derived myeloid cells, such as macrophages and mast cells, have an important role in regulating the formation and maintenance of blood vessels in tumours. How do these cells contribute to this process? The use of various transgenic mouse models and analysis of human tumour biopsies has shown that bone marrow-derived myeloid cells, such as macrophages, neutrophils, eosinophils, mast cells and dendritic cells, have an important role in regulating the formation and maintenance of blood vessels in tumours. In this Review the evidence for each of these cell types driving tumour angiogenesis is outlined, along with the mechanisms regulating their recruitment and activation by the tumour microenvironment. We also discuss the therapeutic implications of recent findings that specific myeloid cell populations modulate the responses of tumours to agents such as chemotherapy and some anti-angiogenic therapies.

31 July 2019 in Nature
Verified
Journal Article
Closed access
PDF file
MWMax D. Wellenstein
Max D. Wellenstein
SCSeth B. Coffelt
Seth B. Coffelt
DDDanique E. M. Duits
Danique E. M. Duits
MMMartine H. van Miltenburg
Martine H. van Miltenburg
MSMaarten Slagter
Maarten Slagter
KVKarin E de Visser
Karin E de Visser

17 June 2019 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
BSBruno Silva-Santos
Bruno Silva-Santos
SMSofia Mensurado
Sofia Mensurado
SCSeth B. Coffelt
Seth B. Coffelt
The potential of cancer immunotherapy relies on the mobilization of immune cells capable of producing antitumour cytokines and effectively killing tumour cells. These are major attributes of γδ T cells, a lymphoid lineage that is often underestimated despite its major role in tumour immune surveillance, which has been established in a variety of preclinical cancer models. This situation notwithstanding, in particular instances the tumour microenvironment seemingly mobilizes γδ T cells with immunosuppressive or tumour-promoting functions, thus emphasizing the importance of regulating γδ T cell responses in order to realize their translation into effective cancer immunotherapies. In this Review we outline both seminal work and recent advances in our understanding of how γδ T cells participate in tumour immunity and how their functions are regulated in experimental models of cancer. We also discuss the current strategies aimed at maximizing the therapeutic potential of human γδ T cells, on the eve of their exploration in cancer clinical trials that may position them as key players in cancer immunotherapy.

4 October 2007 in Stem Cells
Verified
Journal Article
Open access
PDF file
STSuzanne L. Tomchuck
Suzanne L. Tomchuck
KZKevin Zwezdaryk
Kevin Zwezdaryk
SCSeth B. Coffelt
Seth B. Coffelt
RWRuth S. Waterman
Ruth S. Waterman
EDElizabeth S. Danka
Elizabeth S. Danka
ASAline B. Scandurro
Aline B. Scandurro
Adult human bone marrow-derived mesenchymal stem cells (hMSCs) are under study as therapeutic delivery agents that assist in the repair of damaged tissues. To achieve the desired clinical outcomes for this strategy requires a better understanding of the mechanisms that drive the recruitment, migration, and engraftment of hMSCs to the targeted tissues. It is known that hMSCs are recruited to sites of stress or inflammation to fulfill their repair function. It is recognized that toll-like receptors (TLRs) mediate stress responses of other bone marrow-derived cells. This study explored the role of TLRs in mediating stress responses of hMSCs. Accordingly, the presence of TLRs in hMSCs was initially established by reverse transcription-polymerase chain reaction assays. Flow cytometry and fluorescence immunocytochemical analyses confirmed these findings. The stimulation of hMSCs with TLR agonists led to the activation of downstream signaling pathways, including nuclear factor κB, AKT, and MAPK. Consequently, activation of these pathways triggered the induction and secretion of cytokines, chemokines, and related TLR gene products as established from cDNA array, immunoassay, and cytokine antibody array analyses. Interestingly, the unique patterns of affected genes, cytokines, and chemokines measured identify these receptors as critical players in the clinically established immunomodulation observed for hMSCs. Lastly, hMSC migration was promoted by TLR ligand exposure as demonstrated by transwell migration assays. Conversely, disruption of TLRs by neutralizing TLR antibodies compromised hMSC migration. This study defines a novel TLR-driven stress and immune modulating response for hMSCs that is critical to consider in the design of stem cell-based therapies. Disclosure of potential conflicts of interest is found at the end of this article.